NCT04547062View on ClinicalTrials.gov

Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions

Acute Myeloid Leukemia (AML)

Interventions

DRUG

Tocilizumab

Administration of tocilizumab at day 8 of induction following a classical induction

Trial Locations (1)

44093

CHU of Nantes, Nantes

All Listed Sponsors

lead

Nantes University Hospital

OTHER

NCT04547062 - Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML) | Biotech Hunter | Biotech Hunter